HOME >> MEDICINE >> NEWS
'Biochemical storm' following brain trauma, an important factor in treatment

Oct. 28, 1999, GAINESVILLE---A forceful blow to the head can trigger a "Pacman-like" enzyme to begin gobbling up important structural proteins in the brain for up to one month afterward -- weeks longer than previously suspected, according to a University of Florida Brain Institute researcher.

The finding, based on studies in rats, suggests that treatment for traumatic brain injury must take into account tissue damage that continues to occur long after an accident. Although a number of studies recently have assessed therapies for traumatic brain injury, currently no effective treatment exists. "Emergency room medical personnel often talk about a golden hour, that if you don't get a person into treatment within the first hour or so after an injury, a lot of damage has been done to the patient," said Ronald L. Hayes, director of UF's planned Center for Traumatic Brain Injury Studies, a component of the university's multidisciplinary Brain Institute. "With traumatic brain injury, the thought has been that treatment within the first two days is critical." But data from Hayes' lab suggest this critical period may extend much longer.

"In our studies, we've found that a biochemical storm that is initiated with an injury continues for at least a month. The implication is that we may need to treat these patients over a much longer period than anyone had ever imagined," said Hayes, who reported his findings on the action of calpains on Saturday (10/23) at the annual meeting of the National Neurotrauma Society in Miami Beach. Calpains are a type of protein-destroying enzyme found in cells throughout the body.

"This is one of a very few research efforts that opens up a potential window for treatment in which we might be able to suppress the harmful activity of calpains while allowing repair to occur," said Kevin Wang, a senior research associate at Parke-Davis Pharmaceutical Research who is conducting laboratory experiments seeking to block the action of calpa
'"/>

Contact: Victoria White
vickiwhite@xtalwind.net
352-344-2738
University of Florida
27-Oct-1999


Page: 1 2 3

Related medicine news :

1. US FDA grants full approval to DOXIL(R) following submission of phase III data
2. Patients with abdominal trauma at risk for intra-abdominal infections following surgery
3. Guidelines for following pediatric cancer survivors aim to reduce medical complications
4. Can the standard course of radiation therapy following lumpectomy be shortened?
5. Higher incidence of rejection following early steroid withdrawal
6. Impaired neuromotor function following cancer treatment can improve
7. Significant pain relief following gastric bypass surgery
8. Carbon monoxide from smoking helps keep arteries open following angioplasty
9. CellCept associated with reduced incidence of cancer, compared to AZA, following heart transplant
10. Study shows lower than expected allergic-like events following second prescription of penicillin
11. Hospitals following heart attack guidelines have better outcomes

Post Your Comments:
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a ... for two years, the longest of any cellulite reduction system currently on the market. ... effective solution for their cellulite, according to Dr. Robert Weiss, director of the premier ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... abuse, or those who might personally be struggling with chemical dependency, may be ... from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located in ...
(Date:8/28/2015)... ... August 28, 2015 , ... Altima Technologies, Inc., the maker ... data center assets and audio-video devices, recently released Visio Stencils for the following ... ProLiant Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data Systems ...
(Date:8/28/2015)... ... 28, 2015 , ... The Nashville Business Journal recently announced ... business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one ... Veterans Awards will recognize Nashville military veterans who, through their professional and personal ...
(Date:8/28/2015)... Arizona (PRWEB) , ... August 28, 2015 , ... ... and increased patient loyalty at a low cost. Personalized with practice contact information ... and existing patients. Dental offices can also incorporate Calendars into seasonal mailings, thank ...
Breaking Medicine News(10 mins):Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Altima Updates NetZoomâ„¢ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoomâ„¢ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:MyGenetx Board Member Receives Veterans Award 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Quetiapine Market, ... Developed by AstraZeneca plc, quetiapine (under the trade ... the treatment of schizophrenia. Approved by CFDA to ... the Catalogue of Drugs for the Basic National ...
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... Novartis, ranibizumab was approved by CFDA to treat wet ... Lucentis, a product of Novartis, is available in the ... self- developed drug for the treatment of wet AMD ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
Cached News: